GlassScriptPhysician profile
Haroon I Saeed
NPI 1750597696
$8,477.36
in general payments reported to CMS, 2019-2025
12 companies · $2,834 in 2025
The $2,834 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $242 · 2021: $1,363 · 2022: $921 · 2023: $1,724 · 2024: $1,392 · 2025: $2,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,950.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,889.62 | 2020-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $1,850.94 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $1,121.14 | 2020-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $943.54 | 2020-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $939.25 | 2020-2025 | Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $638.96 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $637.59 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Bioxcel Therapeutics, INC. | $305.91 | 2023-2024 | Igalmi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.80 | 2020-2024 | Caplyta |
| Luye Pharma (USA) LTD. | $45.41 | 2025 | Erzofri Extended-Release |
| Corium, LLC | $23.23 | 2023 | Azstarys |
| Indivior INC. | $15.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haroon Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.